Management of Oligometastatic Disease in Advanced Non-Small Cell Lung Cancer.

Non-small cell lung cancer with very limited extent of metastatic spread commonly is termed, oligometastatic disease (OMD), and typically described as no more than 3 to 5 lesions. Definitive local therapy potentially leads to significant improvement in progression-free survival and overall survival. OMD may occur de novo prior to initiation of systemic therapy or as an induced state after initiation of systemic therapy. Although prospective data are limited to small trials, they have consistently supported local therapy as an appropriate consideration if not a clear standard of care for well-selected patients. Several trials in OMD are ongoing.
Competing Interests: Disclosure The author has nothing to disclose.
(Copyright © 2020 Elsevier Inc. All rights reserved.)